Interferon-alpha treatment of patients with Hepatitis C: the role of a comprehensive risk-benefit assessment

CNS Drugs. 2005;19(8):719-21; author reply 721-2. doi: 10.2165/00023210-200519080-00009.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Hepatitis C / drug therapy*
  • Humans
  • Interferon Type I / therapeutic use*
  • Recombinant Proteins
  • Risk Assessment

Substances

  • Antiviral Agents
  • Interferon Type I
  • Recombinant Proteins